ERBB2 and cancer: Plasmonic nanoparticle nhanced “hot-spots” have been exploited for SERS detection of cancer biomarkers [2] including carcinoembryonic antigen (CEA), alpha fetoprotein (AFP), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), prostate-specific antigen (PSA), tumor suppressor p53, epidermal growth factor receptor (EGFR), and neuron-specific enolase (NSE) [1,21].